Please ensure Javascript is enabled for purposes of website accessibility

Why Teladoc Stock Was Sinking Today

By Jeremy Bowman – May 27, 2020 at 12:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the telehealth provider continued to fall as the market rotated out of high-growth stocks.

What happened

Shares of Teladoc (TDOC -3.35%) were slipping today for the second day in a row as investors continued to rotate out of high-flying tech stocks, especially those that have done well during the coronavirus crisis, and into more beaten-down cyclical plays. As the economic reopening picks up steam, investors expect that laggards will bounce back, and they are selling off stocks that have already hit all-time highs during the crisis.

Though there was no specific news on Teladoc, that shift was enough to push the stock lower as shares were down 8.8% at 11 a.m EDT on Wednesday. At the same time, the Nasdaq was off 2%, while the Dow Jones Industrial Average was up 0.4%, illustrating the broader bifurcation between tech stocks and cyclicals like manufacturing, energy, industrials, and consumer discretionary stocks.

A woman and a child looking at a doctor on a tablet

Image source: Getty Images.

So what

Teladoc has been a standout performer during the crisis, and it's easy to see why. As a leader in telehealth, a platform using videoconferencing for doctor visits, Teladoc was seen as a beneficiary from the crisis, which forced doctors' offices to close and patients to stay home. Additionally, as a health crisis, the pandemic may be leading more consumers to seek medical advice if they believe they have the virus.

As the chart below shows, shares surged through the first two months of the crisis, but more recently the stock has pulled back as investors may believe it was overbought.

TDOC Chart

TDOC data by YCharts.

Now what

It's unclear if the pandemic will bring about the revolution in telemedicine that Teladoc investors are hoping for. And with businesses starting to reopen, Americans may be eager to resume the usual in-person doctor visits. 

In the first quarter, Teladoc saw revenue increase 41% to $180.8 million; doctor visits jumped 92% to 2 million. For the full year, the company raised its revenue guidance by $100 million, putting it in a range of $800 million to $825 million, or a 47% increase at the midpoint, indicating that it expects a tailwind from the pandemic. Indeed, management said on the earnings call that it had seen a significant increase in inquiries from new and existing customers because of the pandemic.

There's no doubt that Teladoc is a winner from COVID-19, but the company is still unprofitable, and the stock has run up 150% over the last year. Though the long-term future looks bright, it may be time for the stock to take a breather.

Jeremy Bowman owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$25.35 (-3.35%) $0.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.